Science & Technology · Biotechnology · UPSC GS-III
Personalised Medicine & Pharmacogenomics — Your DNA, Your Drug 🧬💊
Complete UPSC Notes — made easy for non-bio students. What is pharmacogenomics, how it works, why the same drug works differently in different people. With Indian examples (Genome India, CYP2C19, warfarin), real-world applications, ethical concerns, MCQs and linked PYQs.
🧬 Pharmacology + Genomics = Pharmacogenomics
Right Drug → Right Patient → Right Dose
🇮🇳 Genome India → 38 Drug Metabolism Variants
P4 Medicine: Predictive, Preventive, Personalised, Participatory
ADRs = 4th Leading Cause of Death (USA)
📚 Legacy IAS — Civil Services Coaching, Bangalore · Updated: April 2026
Section 01 — Start Here (Zero Bio Knowledge Needed)
🔥 The Problem — Why "One Drug Fits All" Doesn't Work
💡 The Shoe Shop Analogy
Imagine a shoe shop that sells only one size — Size 8. Some people's feet fit perfectly. Some people's feet are too small (the shoe is loose, they trip). Some people's feet are too big (the shoe is tight, they get blisters). Now imagine a shop that measures your foot first and gives you the exact size. That's personalised medicine. Traditional medicine gives everyone the same drug (Size 8). Pharmacogenomics reads your DNA first and gives you the drug that fits YOUR body.
⚠️ The Real Cost of "One Size Fits All": In the USA, adverse drug reactions (ADRs) are estimated to be the 4th–6th leading cause of death — causing over 100,000 deaths and more than 2 million serious injuries per year among hospitalised patients (FDA data). Many of these occur because patients are given drugs that don't match their genetic makeup. Pharmacogenomics aims to prevent this.
❌
Traditional Medicine
Approach
One-size-fits-all — same drug, same dose for everyone
Based on
Symptoms, disease diagnosis, trial-and-error
Problem
Drug works for ~60% of patients. Others get no benefit or side effects.
Example
Doctor prescribes standard blood thinner → some patients bleed excessively, others get no effect
✅
Personalised Medicine
Approach
Right drug, right dose, right patient — tailored to YOUR genes
Based on
Your DNA + symptoms + lifestyle + environment
Result
Higher efficacy, fewer side effects, lower cost
Example
Genetic test → reveals you're a "slow metaboliser" → doctor adjusts dose specifically for you
Section 02
🧬 What is Pharmacogenomics? — Definitions Made Easy
📌 Definition: Pharmacogenomics = Pharmacology (study of drugs) + Genomics (study of genes) = the study of how your genetic makeup affects your body's response to drugs. It is the scientific foundation of personalised/precision medicine.
💡 The "Recipe Book" Analogy
Your DNA is like a recipe book that tells your body how to make enzymes. These enzymes are the workers that break down drugs in your liver. If your recipe book has a typo (a genetic variant), your workers might work too fast (breaking down the drug before it can help you) or too slow (letting the drug accumulate to toxic levels). Pharmacogenomics reads your recipe book before prescribing — so the doctor knows exactly how your workers will handle the drug.
How Pharmacogenomics Works
🧬① Your DNATake a sample (saliva/blood) and read your genes
→
🔍② Find VariantsIdentify genetic variants that affect drug metabolism enzymes
→
📊③ Predict ResponsePredict: will this drug work? Will there be side effects?
→
💊④ Personalise TreatmentRight drug, right dose — tailored to YOUR DNA
📌 Key Concept — Metaboliser Types: Based on your genes, you fall into one of four categories: Poor Metaboliser (drug stays too long → toxicity risk), Intermediate Metaboliser (slightly slow), Normal/Extensive Metaboliser (drug works as expected), Ultra-rapid Metaboliser (drug cleared too fast → no effect). The same dose of the same drug can be life-saving for one person and deadly for another — based purely on their genes.
Section 03 — Applications
🏥 Where is Pharmacogenomics Used Today?
🎗️ Oncology (Cancer)
Tailoring cancer therapies based on tumour genetics and patient DNA. Example: HER2 testing before prescribing Herceptin for breast cancer — only works if tumour is HER2-positive. Companion diagnostics test before treatment.
❤️ Cardiology
Adjusting blood thinner dosages. Example: Warfarin dosing varies 10x between patients based on CYP2C9 and VKORC1 gene variants. Clopidogrel may not work in ~30–35% of South Asians who carry CYP2C19 loss-of-function variants.
🧠 Psychiatry
Selecting the right antidepressant with minimal side effects. Many psychiatric drugs are metabolised by CYP2D6 enzyme — genetic variants cause dramatically different responses. Reduces trial-and-error prescribing.
🦠 Infectious Diseases
Predicting response to antivirals. Example: TB drug Isoniazid — NAT2 gene variants make some patients "slow acetylators" with higher risk of liver toxicity. NIRT (2021) confirmed this in Indian patients.
📋 Real Indian Examples for Answer Writing
💊 Clopidogrel & Indians: Around 30–35% of South Asian populations carry CYP2C19 loss-of-function variants that reduce the effectiveness of the common blood thinner clopidogrel (given after heart stents). Studies at AIIMS have highlighted this mutation's prevalence among North Indian cardiac patients — potentially leading to stent failure if not tested genetically before prescribing.
💊 TB & Isoniazid: NAT2 gene variations in Indians cause some patients to metabolise the TB drug isoniazid too slowly ("slow acetylators"), leading to liver toxicity. A 2021 NIRT study confirmed this — making the case for genetic testing before TB treatment.
🧬 Genome India (2025): Sequenced 10,074 Indian genomes → identified 38 critical genetic variants that affect drug metabolism — the foundation for India-specific pharmacogenomics.
Section 04
🎯 P4 Medicine — The Future Framework
P4 Medicine — The Four Pillars
🔮PredictivePredict diseases before symptoms appear using genetic risk profiling
+
🛡️PreventivePrevent disease through lifestyle changes, vaccines, early interventions
+
🧬PersonalisedTailor treatment to YOUR genes, environment, lifestyle
+
🤝ParticipatoryPatient as partner — active role in health decisions using own data
Section 05 — India Connect
🇮🇳 India's Pharmacogenomics Journey
| Initiative | Year | Key Details | PGx Relevance |
|---|
| Genome India Project | 2020–25 | 10,074 genomes from 85 populations. 180M variants. DBT funded. IISc Bengaluru led. Data at IBDC Faridabad. | 38 critical drug metabolism variants identified — foundation for Indian pharmacogenomics |
| IndiGen Programme | 2019 | CSIR. 1,029 genomes. First pharmacogenomic landscape of Indian population. | Mapped clinically actionable PGx variants in Indians. Found significant differences from global populations. |
| BioPharma SHAKTI | 2026 | ₹10,000 crore. Biologics & biosimilars hub. NIPERs, CDSCO reforms. | Creates ecosystem for India-specific personalised medicines and targeted therapies |
| Human Genome Project | 1990–2003 | First complete human genome. $3 billion, 13 years. | Launched the era of genomic medicine. Made pharmacogenomics possible. |
📌 Why India Needs Its Own PGx Data: Most pharmacogenomic guidelines are based on European/American populations. But Indian populations have unique genetic variants (4,600+ distinct groups). Drugs calibrated for Western genomes may not work the same way in Indians. Genome India fills this critical gap by creating an India-specific reference genome for personalised drug prescribing.
Section 06
⚠️ Challenges & Ethical Concerns
🔒 Privacy
Genetic data is the most sensitive personal data. If leaked, it reveals disease predispositions, ancestry, family relationships. Risk of misuse by insurers, employers.
💰 Cost & Access
Genetic testing is expensive. Risk of creating "genomic inequality" — rich get personalised treatment, poor get one-size-fits-all.
🧪 Incomplete Science
Known PGx markers explain only a small part of drug response variability. Many genes and interactions remain undiscovered.
⚖️ Consent
Patients must understand what genetic testing reveals and how their data will be used. Informed consent is critical but complex.
🏥 Infrastructure
India lacks genetic counsellors, testing labs, and trained physicians in most districts. Rural access is a major barrier.
📜 Regulation
India lacks a comprehensive genetic data protection law. Biotech-PRIDE Guidelines (2021) and FeED Protocol exist, but a dedicated framework is needed.
Section 07 — Practice
📝 UPSC-Style MCQs
Q1Pharmacogenomics is the study of:
a) How drugs are manufactured using genetic engineering
b) How an individual's genetic makeup affects their response to drugs
c) How to modify the genome of pharmaceutical crops
d) How to sequence the genome of pathogenic organisms
Pharmacogenomics = Pharmacology + Genomics = study of how genetic differences affect drug responses. It enables personalised treatment — right drug, right dose, right patient. Answer: (b).
Q2Consider the following:
1. The Genome India Project identified genetic variants affecting drug metabolism in Indians.
2. The IndiGen Programme was funded by the Department of Biotechnology (DBT).
3. Pharmacogenomics can help determine the right dosage of blood thinners like warfarin.
Which is/are correct?
a) 1 and 3 only
b) 2 and 3 only
c) 1, 2 and 3
d) 1 only
Statement 1 ✓ — Genome India found 38 critical drug metabolism variants. Statement 2 ✗ — IndiGen was funded by CSIR, NOT DBT. (Genome India was funded by DBT — a common exam trap!) Statement 3 ✓ — Warfarin dosing varies 10x based on CYP2C9/VKORC1 variants. Answer: (a).
Q3A "poor metaboliser" in pharmacogenomics is a person who:
a) Has a poor diet and cannot absorb medications
b) Cannot afford personalised medicine
c) Has genetic variants that cause drugs to be processed too slowly, increasing toxicity risk
d) Has a weakened immune system that reduces drug efficacy
A "poor metaboliser" has genetic variants (in enzymes like CYP2D6, CYP2C19) that cause them to break down drugs too slowly. The drug stays in the body longer than intended → accumulates → risk of toxicity and adverse reactions. This is why pharmacogenomic testing is done before prescribing. Answer: (c).
Q4"P4 Medicine" stands for:
a) Primary, Preventive, Participatory, Pharmaceutical
b) Predictive, Preventive, Personalised, Participatory
c) Precise, Predictive, Pharmacological, Preventive
d) Population, Personalised, Preventive, Pharmaceutical
P4 Medicine: Predictive (predict disease before symptoms), Preventive (prevent through early action), Personalised (tailor to individual genes), Participatory (patient as active partner). Answer: (b).
Section 08
🧠 Memory Aid
🔑 Lock These In for Prelims Day
PGx
Pharmacology + Genomics = study of how genes affect drug response. Foundation of personalised medicine.
SHOE
Traditional medicine = one-size shoe for all. Personalised medicine = measure foot first, then give the right shoe.
ADRs
Adverse Drug Reactions = 4th–6th leading cause of death (USA). Over 100,000 deaths/year in hospitals (FDA). PGx can prevent most of these.
CYP
CYP enzymes (CYP2C19, CYP2D6, CYP2C9) = key drug metabolism enzymes. Genetic variants in these → different metaboliser types.
4 TYPES
Poor (too slow → toxicity), Intermediate, Normal/Extensive (works as expected), Ultra-rapid (too fast → no effect).
30–35%
~30–35% of South Asians carry CYP2C19 loss-of-function variants → clopidogrel (blood thinner) may not work → stent failure risk.
GENOME
Genome India found 38 drug metabolism variants in Indians. IndiGen (CSIR, 1,029 genomes) first mapped Indian PGx landscape.
P4
Predictive + Preventive + Personalised + Participatory = future of medicine.
CSIR vs DBT
IndiGen = CSIR. Genome India = DBT. Don't confuse! UPSC loves this trap.
WARFARIN
Blood thinner. Dosing varies 10x between patients based on CYP2C9 + VKORC1 genes. Classic PGx example.
Section 09
❓ FAQs
What is the difference between pharmacogenomics and pharmacogenetics?
Pharmacogenetics (older term) focuses on how single genes affect drug response — one gene, one drug. Pharmacogenomics (newer, broader term) studies how the entire genome (all genes together) affects drug response — multiple genes, multiple drugs, plus environmental interactions. Think of pharmacogenetics as studying one tree and pharmacogenomics as studying the whole forest. In practice, UPSC treats them as interchangeable — but technically, pharmacogenomics is the broader field.
How is pharmacogenomics different from gene therapy?
Pharmacogenomics = reading your genes to choose the right drug. Your genes are NOT changed — they are just read as a guide. Gene therapy = actually changing your genes to fix a genetic defect (e.g., Casgevy for sickle cell). Pharmacogenomics is like reading a map to choose the best route; gene therapy is like rebuilding the road itself.
Why does warfarin dosing vary so much between patients?
Warfarin (a blood thinner) is metabolised by the CYP2C9 enzyme and works by blocking the VKORC1 protein. Genetic variants in both genes cause the effective dose to vary by more than 10-fold between patients. A patient with a "sensitive" VKORC1 variant given a standard dose could experience dangerous internal bleeding. This is why warfarin is the most cited example in pharmacogenomics — and why genetic testing before prescribing is now recommended in many countries.
Is pharmacogenomic testing available in India?
Yes, but it is limited and expensive. Some private labs (like Mapmygenome, Medgenome, Strand Life Sciences — all India-based companies) offer pharmacogenomic testing panels. However: (1) Most hospitals don't routinely offer it. (2) Cost ranges from ₹5,000–50,000 per test. (3) There are very few trained genetic counsellors in India. (4) India lacks population-specific PGx guidelines — most guidelines are based on Western populations. The Genome India Project and IndiGen data will eventually help create India-specific guidelines, but clinical implementation is still in early stages.
Section 10 — Mains
📜 Probable Mains Questions
Probable Question 1
"What is pharmacogenomics? How does it contribute to personalised medicine? Discuss with examples from the Indian context."
Probable Question 2
"Discuss the significance of the Genome India Project for pharmacogenomics and precision medicine in India. What challenges does its implementation face?"
Probable Question 3
"What are the ethical concerns associated with the use of genetic data in personalised medicine? How can India address these while advancing its genomic medicine capabilities?"
Section 11
🏁 Conclusion
🧬💊 Your DNA, Your Drug
Every year, millions of people take drugs that don't work for them — or worse, that harm them. The reason is simple: we've been prescribing medicines based on the disease, not the patient. Pharmacogenomics changes that equation. By reading a patient's genetic code before prescribing, doctors can predict which drug will work, which will cause side effects, and what dose will be effective — turning medicine from a game of trial-and-error into a science of precision.
India is uniquely positioned for this revolution. With 4,600+ genetically distinct population groups and the Genome India Project having mapped 10,074 of them, India now has the data to build its own pharmacogenomic framework. The discovery that 35% of Indians carry a CYP2C19 mutation affecting a common heart drug — a fact invisible in Western databases — shows exactly why India-specific genomic data matters.
For UPSC: Remember the definition (pharmacology + genomics), the "shoe shop" analogy, the 4 metaboliser types, the Indian examples (clopidogrel/CYP2C19 in 35% Indians, warfarin/CYP2C9, TB/NAT2), the P4 framework, and the CSIR (IndiGen) vs DBT (Genome India) distinction.
